Berries and other natural products in pancreatic cancer chemoprevention in human clinical trials

Journal of Berry Research

Volumn 7, Issue 3, 2017, Pages 147-161

  Pan, Pan ^a   Skaer, Chad ^a   Yu, Jianhua ^b   Zhao, Hui ^c   Ren, He ^d   Oshima, Kiyoko ^e   Wang, Li Shu ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c TIANJIN UNIVERSITY OF COMMERCE   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Berries; cancer immunology; human clinical trials; natural products; pancreatic cancer

Indexed keywords

EID: 85027888308     PISSN: 18785093     EISSN: 18785123     Source Type: Journal    
DOI: 10.3233/JBR-170159     Document Type: Review

References (73)

1. World Cancer Research Fund International: Pancreatic cancer statistics. Available at: Http://www.wcrf.org/int/cancer-factsfigures/data-specific-cancers/pancreatic-cancer-statistics. Accessed April 13, 2017.
2. StewartBWWC.World Cancer Report 2014. Available at: Http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014. Accessed April 6, 2017.
3. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30. doi: 10.3322/caac.21387
4. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913-21. doi: 10.1158/0008-5472.CAN-14-0155
5. Quante AS, Ming C, Rottmann M, Engel J, Boeck S, Heinemann V, et al. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med. 2016;5(9):2649-56. doi: 10.1002/cam4.767
6. American Cancer Society: Pancreatic Cancer Risk Factors. Available at: Https://www.cancer.org/cancer/pancreatic-cancer/causesrisks-prevention/risk-factors.html. Acessed April 13, 2017.
7. Wiseman M. The secondWorld Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: A global perspective. Proc Nutr Soc. 2008;67(3):253-6. doi: 10.1017/S002966510800712X
8. Amayo AA, Kuria JG. Clinical application of tumour markers: A review. East African Medical Journal. 2009;86(12 Suppl):S76-83.
9. Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012;23(7):1713-22. doi: 10.1093/annonc/mdr561
10. Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol. 2014;20(32):11142-59. doi: 10.3748/wjg.v20.i32.11142
11. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 1997;15(6):2403-13. doi: 10.1200/jco.1997.15.6.2403
12. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691-703. doi: 10.1056/NEJMoa1304369
13. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-25. doi: 10.1056/NEJMoa1011923
14. Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dorken B, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47(11):1676-81. doi: 10.1016/j.ejca.2011.04.011
15. Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: Outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32(23):2423-9. doi: 10.1200/JCO.2013.53.6995
16. Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545-57. doi: 10.1016/S0140-6736(15)00986-1
17. Ruess DA, Gorgulu K, Wormann SM, Algul H. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Drugs Aging. 2017;34(5):331-57. doi: 10.1007/s40266-017-0453-y
18. Stan SD, Singh SV, Brand RE. Chemoprevention strategies for pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2010;7(6):347-56. doi: 10.1038/nrgastro.2010.61
19. Boreddy SR, Srivastava SK. Pancreatic cancer chemoprevention by phytochemicals. Cancer Lett. 2013;334(1):86-94. doi: 10.1016/j.canlet.2012.10.020
20. Categorical Glossary for the Flora of North America Project. http://fmhibd.library.cmu.edu/HIBD-DB/FNA/recordlist.php
21. Wang LS, Burke CA, Hasson H, Kuo CT, Molmenti CL, Seguin C, et al. A phase Ib study of the effects of black raspberries on rectal polyps in patients with familial adenomatous polyposis. Cancer Prev Res (Phila). 2014;7(7):666-74. doi: 10.1158/1940-6207.CAPR-14-0052
22. Wang LS, Arnold M, Huang YW, Sardo C, Seguin C, Martin E, et al. Modulation of genetic and epigenetic biomarkers of colorectal cancer in humans by black raspberries: A phase I pilot study. Clin Cancer Res. 2011;17(3):598-610. doi: 10.1158/1078-0432.CCR-10-1260
23. Pan P, Skaer CW, Stirdivant SM, Young MR, Stoner GD, Lechner JF, et al. Beneficial regulation of metabolic profiles by black raspberries in human colorectal cancer patients. Cancer Prev Res (Phila). 2015;8(8):743-50. doi: 10.1158/1940-6207.CAPR-15-0065
24. Pan P, Skaer CW, Wang HT, Stirdivant SM, Young MR, Oshima K, et al. Black raspberries suppress colonic adenoma development in ApcMin/+ mice: Relation to metabolite profiles. Carcinogenesis. 2015;36(10):1245-53. doi: 10.1093/carcin/bgv117
25. Pan P, Skaer CW, Wang HT, Oshima K, Huang YW, Yu J, et al. Loss of free fatty acid receptor 2 enhances colonic adenoma development and reduces the chemopreventive effects of black raspberries in ApcMin/+ mice. Carcinogenesis. 2017;38(1):86-93. doi: 10.1093/carcin/bgw122
26. Pan P, Skaer CW, Wang HT, Kreiser MA, Stirdivant SM, Oshima K, et al. Systemic metabolite changes in wild-type C57BL/6 mice fed black raspberries. Nutr Cancer. 2017;69(2):299-306. doi: 10.1080/01635581.2017.1263748
27. Pan P, Skaer C, Wang HT, Tsai S, Oshima K, Huang Y-W, et al. Abstract LB-268: Black rapsberries induced protection in pancreatic cancer mouse models. Cancer Research. 2015;75(15 Supplement):268.
28. Pan P, Skaer CW, Wang H-T, Tsai S, Oshima K, Huang Y-W, et al. Abstract B59: Black raspberries inhibit pancreatic carcinogenesis by suppressing Raf/MEK/ERK/STAT3 signaling pathways and promoting apoptosis. Cancer Research. 2016;76(24 Supplement): B59.
29. Westphalen CB, Olive KP. Genetically engineered mouse models of pancreatic cancer. Cancer J. 2012;18(6):502-10. doi: 10.1097/PPO.0b013e31827ab4c4
30. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7(5):469-83. doi: 10.1016/j.ccr.2005.04.023
31. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18(16):4266-76. doi: 10.1158/1078-0432.CCR-11-3114
32. Bosma M, Schuler W, Bosma G. The scid mouse mutant. Curr Top Microbiol Immunol. 1988;137:197-202.
33. Mannal PW, Alosi JA, Schneider JG, McDonald DE, McFadden DW. Pterostilbene inhibits pancreatic cancer in vitro. J Gastrointest Surg. 2010;14(5):873-9. doi: 10.1007/s11605-010-1164-4
34. Cedo L, Castell-Auvi A, Pallares V, Macia A, Blay M, Ardevol A, et al. Gallic acid is an active component for the anticarcinogenic action of grape seed procyanidins in pancreatic cancer cells. Nutr Cancer. 2014;66(1):88-96. doi: 10.1080/01635581.2014.851714
35. Prasad R, Vaid M, Katiyar SK. Grape proanthocyanidin inhibit pancreatic cancer cell growth in vitro and in vivo through induction of apoptosis and by targeting the PI3K/Akt pathway. PLoS One. 2012;7(8):e43064. doi: 10.1371/journal.pone.0043064
36. Prasad R, Katiyar SK. Grape seed proanthocyanidins inhibit migration potential of pancreatic cancer cells by promoting mesenchymalto-epithelial transition and targeting NF-kappaB. Cancer Lett. 2013;334(1):118-26. doi: 10.1016/j.canlet.2012.08.003
37. Chung YC, Huang CC, Chen CH, Chiang HC, Chen KB, Chen YJ, et al. Grape-seed procyanidins inhibit the in vitro growth and invasion of pancreatic carcinoma cells. Pancreas. 2012;41(3):447-54. doi: 10.1097/MPA.0b013e318229da41
38. Golkar L, Ding XZ, Ujiki MB, Salabat MR, Kelly DL, Scholtens D, et al. Resveratrol inhibits pancreatic cancer cell proliferation through transcriptional induction of macrophage inhibitory cytokine-1. J Surg Res. 2007;138(2):163-9. doi: 10.1016/j.jss.2006.05.037
39. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Research. 2003;23(1a):363-98.
40. Li N, Chen X, Liao J, Yang G, Wang S, Josephson Y, et al. Inhibition of 7, 12-dimethylbenz [a]anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. Carcinogenesis. 2002;23(8):1307-13.
41. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: How many ways can curry kill tumor cells selectively? The AAPS Journal. 2009;11(3):495-510. doi: 10.1208/s12248-009-9128-x
42. Sarkar FH, Li Y, Wang Z, Padhye S. Lesson learned from nature for the development of novel anti-cancer agents: Implication of isoflavone, curcumin, and their synthetic analogs. Current Pharmaceutical Design. 2010;16(16):1801-12.
43. Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol. 2011;68(1):157-64. doi: 10.1007/s00280-010-1470-2
44. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14(14):4491-9. doi: 10.1158/1078-0432.CCR-08-0024
45. Epelbaum R, Schaffer M, Vizel B, Badmaev V, Bar-Sela G. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer. 2010;62(8):1137-41. doi: 10.1080/01635581.2010.513802
46. Parsons HA, Baracos VE, Hong DS, Abbruzzese J, Bruera E, Kurzrock R. The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer. Oncotarget. 2016;7(15):20293-304. doi: 10.18632/oncotarget.7773
47. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: Problems and promises. Molecular pharmaceutics. 2007;4(6):807-18. doi: 10.1021/mp700113r
48. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica. 1998;64(4):353-6. doi: 10.1055/s-2006-957450
49. Sato A, Kudo C, Yamakoshi H, Uehara Y, Ohori H, Ishioka C, et al. Curcumin analog GO-Y030 is a novel inhibitor of IKKbeta that suppresses NF-kappaB signaling and induces apoptosis. Cancer Sci. 2011;102(5):1045-51. doi: 10.1111/j.1349-7006.2011. 01886.x
50. Bao B, Ali S, Banerjee S, Wang Z, Logna F, Azmi AS, et al. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res. 2012;72(1):335-45. doi: 10.1158/0008-5472.CAN-11-2182
51. Dandawate PR, Vyas A, Ahmad A, Banerjee S, Deshpande J, Swamy KV, et al. Inclusion complex of novel curcumin analogue CDF and beta-cyclodextrin (1:2) and its enhanced in vivo anticancer activity against pancreatic cancer. Pharmaceutical Research. 2012;29(7):1775-86. doi: 10.1007/s11095-012-0700-1
52. Bimonte S, Barbieri A, Palma G, Luciano A, Rea D, Arra C. Curcumin inhibits tumor growth and angiogenesis in an orthotopic mouse model of human pancreatic cancer. Biomed Res Int. 2013;2013:810423. doi: 10.1155/2013/810423
53. Shevchenko I, Karakhanova S, Soltek S, Link J, Bayry J, Werner J, et al. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int J Cancer. 2013;133(1):98-107. doi: 10.1002/ijc.27990
54. Arshad A, Al-Leswas D, Al-Taan O, Stephenson J, Metcalfe M, Steward WP, et al. Pooled survival and response data from phase III randomized controlled trials for gemcitabine-based regimes in the treatment of advanced pancreatic cancer. American Journal of Clinical Oncology. 2013;36(4):411-4. doi: 10.1097/COC.0b013e3182124216
55. Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res. 2006;12(18):5277-87. doi: 10.1158/1078-0432.CCR-06-0436
56. Hiura A, Tsutsumi M, Satake K. Inhibitory effect of green tea extract on the process of pancreatic carcinogenesis induced by Nnitrosobis-( 2-oxypropyl)amine (BOP) and on tumor promotion after transplantation of N-nitrosobis-(2-hydroxypropyl)amine (BHP)-induced pancreatic cancer in Syrian hamsters. Pancreas. 1997;15(3):272-7.
57. Bimonte S, Leongito M, Barbieri A, Del Vecchio V, Barbieri M, Albino V, et al. Inhibitory effect of (-)-epigallocatechin-3-gallate and bleomycin on human pancreatic cancer MiaPaca-2 cell growth. Infect Agent Cancer. 2015;10:22. doi: 10.1186/s13027-015-0016-y
58. Majima T, Tsutsumi M, Nishino H, Tsunoda T, KonishiY. Inhibitory effects of beta-carotene, palm carotene, and green tea polyphenols on pancreatic carcinogenesis initiated by N-nitorsobis(2-oxopropyl)amine in Syrian golden hamsters. Pancreas. 1998;16(1):13-8.
59. Qanungo S, Das M, Haldar S, Basu A. Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspasedependent apoptosis in pancreatic cancer cells. Carcinogenesis. 2005;26(5):958-67. doi: 10.1093/carcin/bgi040
60. Shankar S, Ganapathy S, Hingorani SR, Srivastava RK. EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci. 2008;13:440-52.
61. Shankar S, Marsh L, Srivastava RK. EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1/FOXO3a and neuropilin. Molecular and Cellular Biochemistry. 2013;372(1-2):83-94. doi: 10.1007/s11010-012-1448-y
62. Zhu Z, Wang Y, Liu Z, Wang F, Zhao Q. Inhibitory effects of epigallocatechin-3-gallate on cell proliferation and the expression of HIF-1alpha and P-gp in the human pancreatic carcinoma cell line PANC-1. Oncology Reports. 2012;27(5):1567-72. doi: 10.3892/or.2012.1697
63. Lyn-Cook BD, RogersT, YanY, Blann EB, Kadlubar FF, HammonsGJ. Chemopreventive effects of tea extracts and various components on human pancreatic and prostate tumor cells in vitro. Nutr Cancer. 1999;35(1):80-6. doi: 10.1207/S1532791480-86
64. Anissi J, El Hassouni M, Ouardaoui A, Sendide K. A comparative study of the antioxidant scavenging activity of green tea, black tea and coffee extracts: A kinetic approach. Food Chem. 2014;150:438-47. doi: 10.1016/j.foodchem.2013.11.009
65. Basu A, BettsNM, Mulugeta A, Tong C, Newman E, Lyons TJ. Green tea supplementation increases glutathione and plasma antioxidant capacity in adults with the metabolic syndrome. Nutr Res. 2013;33(3):180-7. doi: 10.1016/j.nutres.2012.12.010
66. Frei B, Higdon JV. Antioxidant activity of tea polyphenols in vivo: Evidence from animal studies. The Journal of Nutrition. 2003;133(10):3275s-84s.
67. Guo Q, Zhao B, Shen S, Hou J, Hu J, Xin W. ESR study on the structure-antioxidant activity relationship of tea catechins and their epimers. Biochimica et Biophysica Acta. 1999;1427(1):13-23.
68. Nakagawa T, Yokozawa T. Direct scavenging of nitric oxide and superoxide by green tea. Food and chemical toxicology: An international journal published for the British Industrial Biological Research Association. 2002;40(12):1745-50.
69. Nanjo F, Honda M, Okushio K, Matsumoto N, Ishigaki F, Ishigami T, et al. Effects of dietary tea catechins on alpha-tocopherol levels, lipid peroxidation, and erythrocyte deformability in rats fed on high palm oil and perilla oil diets. Biol Pharm Bull. 1993;16(11):1156-9.
70. Newsome BJ, Petriello MC, Han SG, Murphy MO, Eske KE, Sunkara M, et al. Green tea diet decreases PCB 126-induced oxidative stress in mice by up-regulating antioxidant enzymes. The Journal of Nutritional Biochemistry. 2014;25(2):126-35. doi: 10.1016/j.jnutbio.2013.10.003
71. Kostin SF, McDonald DE, McFadden DW. Inhibitory effects of (-)-epigallocatechin-3-gallate and pterostilbene on pancreatic cancer growth in vitro. J Surg Res. 2012;177(2):255-62. doi: 10.1016/j.jss.2012.04.023
72. BragaM, Bissolati M, Rocchetti S, Beneduce A, Pecorelli N, Di CarloV. Oral preoperative antioxidants in pancreatic surgery:Adoubleblind, randomized, clinical trial. Nutrition (Burbank, Los Angeles County, Calif). 2012;28(2):160-4. doi: 10.1016/j.nut.2011.05.014
73. Ji BT, Chow WH, Hsing AW, McLaughlin JK, Dai Q, Gao YT, et al. Green tea consumption and the risk of pancreatic and colorectal cancers. Int J Cancer. 1997;70(3):255-8.